重新审视钠-葡萄糖共转运蛋白抑制剂在1型糖尿病中的益处与风险。A部分：钠-葡萄糖共转运蛋白抑制剂在1型糖尿病中的益处

IF 6.1 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2025-05-23 DOI:10.1016/j.diabres.2025.112278

Jennifer Ngan , David N O’Neal , Melissa H Lee , Yee Wen Kong , Richard J MacIsaac

{"title":"重新审视钠-葡萄糖共转运蛋白抑制剂在1型糖尿病中的益处与风险。A部分：钠-葡萄糖共转运蛋白抑制剂在1型糖尿病中的益处","authors":"Jennifer Ngan , David N O’Neal , Melissa H Lee , Yee Wen Kong , Richard J MacIsaac","doi":"10.1016/j.diabres.2025.112278","DOIUrl":null,"url":null,"abstract":"<div><div>There has been increasing research into non-insulin therapies to assist people living with type 1 diabetes (T1D) improve their glucose control and to help prevent the development and progression of vascular and kidney complications. In particular, the sodium-glucose co-transporter (SGLT) inhibitor class of medication has received attention as an adjunctive therapy in T1D. These medications have an established and important role in the management of type 2 diabetes, heart failure and chronic kidney disease. Unfortunately, SGLT inhibitors, especially when taken during periods of fasting or intercurrent illness, can precipitate diabetic ketoacidosis. Considering the above, SGLT inhibitors have failed to obtain an indication for use in the setting of T1D. Here we review the potential glycaemic, cardiovascular and kidney benefits of SGLT inhibitors for people with T1D.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112278"},"PeriodicalIF":6.1000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes Part A: Benefits of sodium-glucose co-transporter inhibitor use in type 1 diabetes\",\"authors\":\"Jennifer Ngan , David N O’Neal , Melissa H Lee , Yee Wen Kong , Richard J MacIsaac\",\"doi\":\"10.1016/j.diabres.2025.112278\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>There has been increasing research into non-insulin therapies to assist people living with type 1 diabetes (T1D) improve their glucose control and to help prevent the development and progression of vascular and kidney complications. In particular, the sodium-glucose co-transporter (SGLT) inhibitor class of medication has received attention as an adjunctive therapy in T1D. These medications have an established and important role in the management of type 2 diabetes, heart failure and chronic kidney disease. Unfortunately, SGLT inhibitors, especially when taken during periods of fasting or intercurrent illness, can precipitate diabetic ketoacidosis. Considering the above, SGLT inhibitors have failed to obtain an indication for use in the setting of T1D. Here we review the potential glycaemic, cardiovascular and kidney benefits of SGLT inhibitors for people with T1D.</div></div>\",\"PeriodicalId\":11249,\"journal\":{\"name\":\"Diabetes research and clinical practice\",\"volume\":\"225 \",\"pages\":\"Article 112278\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes research and clinical practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S016882272500292X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S016882272500292X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

越来越多的研究表明，非胰岛素疗法可以帮助1型糖尿病患者改善血糖控制，并有助于预防血管和肾脏并发症的发生和发展。特别是，钠-葡萄糖共转运体（SGLT）抑制剂类药物作为T1D的辅助治疗受到了关注。这些药物在2型糖尿病、心力衰竭和慢性肾脏疾病的治疗中发挥了重要作用。不幸的是，SGLT抑制剂，特别是在禁食或疾病期间服用时，可导致糖尿病酮症酸中毒（DKA）。综上所述，SGLT抑制剂未能获得用于T1D的适应症。在这里，我们回顾了SGLT抑制剂对T1D患者的潜在血糖、心血管和肾脏益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes Part A: Benefits of sodium-glucose co-transporter inhibitor use in type 1 diabetes

There has been increasing research into non-insulin therapies to assist people living with type 1 diabetes (T1D) improve their glucose control and to help prevent the development and progression of vascular and kidney complications. In particular, the sodium-glucose co-transporter (SGLT) inhibitor class of medication has received attention as an adjunctive therapy in T1D. These medications have an established and important role in the management of type 2 diabetes, heart failure and chronic kidney disease. Unfortunately, SGLT inhibitors, especially when taken during periods of fasting or intercurrent illness, can precipitate diabetic ketoacidosis. Considering the above, SGLT inhibitors have failed to obtain an indication for use in the setting of T1D. Here we review the potential glycaemic, cardiovascular and kidney benefits of SGLT inhibitors for people with T1D.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.